|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DDHD2 |
Gene summary for DDHD2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DDHD2 | Gene ID | 23259 |
| Gene name | DDHD domain containing 2 | |
| Gene Alias | SAMWD1 | |
| Cytomap | 8p11.23 | |
| Gene Type | protein-coding | GO ID | GO:0000266 | UniProtAcc | O94830 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23259 | DDHD2 | LZE4T | Human | Esophagus | ESCC | 1.76e-09 | 2.45e-01 | 0.0811 |
| 23259 | DDHD2 | LZE24T | Human | Esophagus | ESCC | 2.54e-06 | 2.39e-01 | 0.0596 |
| 23259 | DDHD2 | P1T-E | Human | Esophagus | ESCC | 8.78e-06 | 1.32e-01 | 0.0875 |
| 23259 | DDHD2 | P2T-E | Human | Esophagus | ESCC | 9.08e-22 | 2.88e-01 | 0.1177 |
| 23259 | DDHD2 | P4T-E | Human | Esophagus | ESCC | 1.38e-12 | 3.02e-01 | 0.1323 |
| 23259 | DDHD2 | P8T-E | Human | Esophagus | ESCC | 2.55e-11 | 1.56e-01 | 0.0889 |
| 23259 | DDHD2 | P9T-E | Human | Esophagus | ESCC | 8.56e-09 | 6.52e-02 | 0.1131 |
| 23259 | DDHD2 | P10T-E | Human | Esophagus | ESCC | 1.07e-25 | 3.91e-01 | 0.116 |
| 23259 | DDHD2 | P11T-E | Human | Esophagus | ESCC | 1.32e-03 | 1.32e-01 | 0.1426 |
| 23259 | DDHD2 | P12T-E | Human | Esophagus | ESCC | 2.06e-14 | 3.33e-01 | 0.1122 |
| 23259 | DDHD2 | P15T-E | Human | Esophagus | ESCC | 1.11e-29 | 6.99e-01 | 0.1149 |
| 23259 | DDHD2 | P16T-E | Human | Esophagus | ESCC | 6.79e-13 | 1.12e-01 | 0.1153 |
| 23259 | DDHD2 | P17T-E | Human | Esophagus | ESCC | 6.14e-03 | 1.63e-01 | 0.1278 |
| 23259 | DDHD2 | P19T-E | Human | Esophagus | ESCC | 5.33e-04 | 4.81e-01 | 0.1662 |
| 23259 | DDHD2 | P20T-E | Human | Esophagus | ESCC | 3.19e-17 | 2.17e-01 | 0.1124 |
| 23259 | DDHD2 | P21T-E | Human | Esophagus | ESCC | 8.92e-17 | 2.46e-01 | 0.1617 |
| 23259 | DDHD2 | P22T-E | Human | Esophagus | ESCC | 7.04e-15 | 1.62e-01 | 0.1236 |
| 23259 | DDHD2 | P23T-E | Human | Esophagus | ESCC | 1.30e-13 | 2.40e-01 | 0.108 |
| 23259 | DDHD2 | P24T-E | Human | Esophagus | ESCC | 3.97e-12 | 1.08e-01 | 0.1287 |
| 23259 | DDHD2 | P26T-E | Human | Esophagus | ESCC | 6.35e-14 | 1.64e-01 | 0.1276 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
| GO:0010821110 | Esophagus | ESCC | regulation of mitochondrion organization | 107/8552 | 144/18723 | 2.31e-12 | 9.41e-11 | 107 |
| GO:000931419 | Esophagus | ESCC | response to radiation | 277/8552 | 456/18723 | 4.42e-11 | 1.43e-09 | 277 |
| GO:001082215 | Esophagus | ESCC | positive regulation of mitochondrion organization | 58/8552 | 74/18723 | 8.55e-09 | 1.73e-07 | 58 |
| GO:000941611 | Esophagus | ESCC | response to light stimulus | 183/8552 | 320/18723 | 2.03e-05 | 1.76e-04 | 183 |
| GO:00464864 | Esophagus | ESCC | glycerolipid metabolic process | 211/8552 | 392/18723 | 6.51e-04 | 3.46e-03 | 211 |
| GO:00442427 | Esophagus | ESCC | cellular lipid catabolic process | 121/8552 | 214/18723 | 8.63e-04 | 4.43e-03 | 121 |
| GO:00901411 | Esophagus | ESCC | positive regulation of mitochondrial fission | 16/8552 | 21/18723 | 4.47e-03 | 1.76e-02 | 16 |
| GO:00002662 | Esophagus | ESCC | mitochondrial fission | 28/8552 | 42/18723 | 4.90e-03 | 1.89e-02 | 28 |
| GO:00160427 | Esophagus | ESCC | lipid catabolic process | 168/8552 | 320/18723 | 7.97e-03 | 2.84e-02 | 168 |
| GO:00482852 | Oral cavity | OSCC | organelle fission | 265/7305 | 488/18723 | 3.22e-12 | 1.27e-10 | 265 |
| GO:001082117 | Oral cavity | OSCC | regulation of mitochondrion organization | 97/7305 | 144/18723 | 4.78e-12 | 1.83e-10 | 97 |
| GO:000931416 | Oral cavity | OSCC | response to radiation | 241/7305 | 456/18723 | 9.76e-10 | 2.40e-08 | 241 |
| GO:00108227 | Oral cavity | OSCC | positive regulation of mitochondrion organization | 53/7305 | 74/18723 | 1.26e-08 | 2.55e-07 | 53 |
| GO:00094164 | Oral cavity | OSCC | response to light stimulus | 159/7305 | 320/18723 | 5.98e-05 | 4.92e-04 | 159 |
| GO:00442426 | Oral cavity | OSCC | cellular lipid catabolic process | 104/7305 | 214/18723 | 2.61e-03 | 1.15e-02 | 104 |
| GO:0090141 | Oral cavity | OSCC | positive regulation of mitochondrial fission | 15/7305 | 21/18723 | 2.65e-03 | 1.16e-02 | 15 |
| GO:00002661 | Oral cavity | OSCC | mitochondrial fission | 24/7305 | 42/18723 | 1.30e-02 | 4.34e-02 | 24 |
| GO:001082118 | Oral cavity | LP | regulation of mitochondrion organization | 65/4623 | 144/18723 | 6.61e-08 | 2.24e-06 | 65 |
| GO:000931417 | Oral cavity | LP | response to radiation | 155/4623 | 456/18723 | 4.12e-06 | 8.49e-05 | 155 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DDHD2 | SNV | Missense_Mutation | c.1150N>G | p.Gln384Glu | p.Q384E | O94830 | protein_coding | tolerated(0.89) | benign(0.001) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| DDHD2 | SNV | Missense_Mutation | c.2132A>G | p.Gln711Arg | p.Q711R | O94830 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.549) | TCGA-A8-A093-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| DDHD2 | SNV | Missense_Mutation | novel | c.1922N>C | p.Val641Ala | p.V641A | O94830 | protein_coding | tolerated(0.85) | benign(0.009) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DDHD2 | SNV | Missense_Mutation | rs776283403 | c.2068N>G | p.Thr690Ala | p.T690A | O94830 | protein_coding | deleterious(0.02) | possibly_damaging(0.576) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
| DDHD2 | SNV | Missense_Mutation | novel | c.1929N>C | p.Glu643Asp | p.E643D | O94830 | protein_coding | tolerated(0.43) | benign(0.012) | TCGA-E9-A3Q9-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphane | CR |
| DDHD2 | insertion | Frame_Shift_Ins | novel | c.866_867insCCTGCCCAGCATTAACCGCCACCCTTCCAACCCCTTCCAAATTT | p.Leu296HisfsTer47 | p.L296Hfs*47 | O94830 | protein_coding | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| DDHD2 | SNV | Missense_Mutation | c.1927N>C | p.Glu643Gln | p.E643Q | O94830 | protein_coding | tolerated(0.17) | benign(0.141) | TCGA-EA-A5ZF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| DDHD2 | SNV | Missense_Mutation | c.191C>T | p.Ser64Leu | p.S64L | O94830 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EK-A2R7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| DDHD2 | insertion | Frame_Shift_Ins | novel | c.362_363insCTCTCCC | p.Lys121AsnfsTer6 | p.K121Nfs*6 | O94830 | protein_coding | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD | ||
| DDHD2 | SNV | Missense_Mutation | rs763476356 | c.1973G>A | p.Arg658His | p.R658H | O94830 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |